The U.S. Food and Drug Administration (FDA) has launched an investigation into the potential risks associated with the use of diabetes and weight-loss drugs like Ozempic, Wegovy, Mounjaro, and Zepbound. The federal agency is examining reports of adverse side effects, such as hair loss, suicidal ideation, and aspiration, linked to these medications. Glucagon-like peptide-1 (GLP-1) …

FDA Investigates Ozempic, Other Diabetes and Weight-Loss Drugs for Suicide, Hair Loss Side Effects Read More »